After successfully shepherding a Zika vaccine candidate into the clinic before any other developer, Inovio Pharmaceuticals is amping up its efforts in HIV.
Seeking to deliver the “final nail in the coffin for HIV,” NIH scientists have kicked off a large clinical trial of a vaccine regimen this week in South Africa.
A team of scientists from Australia is making progress in developing a vaccine that protects the human “surfaces” most likely to encounter the virus first.
It’s another silver lining for drugmakers targeting HIV: Researchers have found promise in a combo of a Johnson & Johnson vaccine and a Gilead immune booster.
Seeking to address a top public health priority, China’s Yisheng Biopharma has teamed with The Scripps Research Institute (TSRI) to advance vaccine research against HIV.
As it works to advance an HIV vaccine candidate, the University of Maryland’s Institute of Human Virology this week received a $14.4 million grant for its research team led by veteran HIV researcher Dr. Robert Gallo.
An HIV vaccine research team led by Texas Biomedical Research Institute has secured $23 million in NIH grant funding to explore an approach that will utilize three lines of defense to protect against the virus.
